Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity
Rhea-AI Summary
Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT), a China-based veterinary vaccine manufacturer, issued a statement responding to recent unusual trading activity in its Class A ordinary shares. The company stated it is not aware of any material non-public information about its business, financial condition, or operations that would explain the recent price and volume movements. Operations are continuing in the ordinary course, and management reports no undisclosed corporate developments or transactions linked to the volatility. Zhengye has contacted Nasdaq regarding the trading activity and will cooperate with Nasdaq and other regulators as appropriate. The company advises investors to exercise caution and rely on information in its SEC filings. Zhengye focuses on livestock vaccines, offering 50 veterinary vaccines across China and certain overseas markets.
Positive
- None.
Negative
- None.
News Market Reaction – ZYBT
In the Jul 21 session, ZYBT declined 64.42%, reflecting a significant negative market reaction. Argus tracked a peak move of +164.9% during that session. Argus tracked a trough of -60.8% from its starting point during tracking. Our momentum scanner triggered 274 alerts that day, indicating exceptionally high trading interest and price volatility. Trading volume was very high at 4.5x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 04 | Nasdaq deficiency notice | Negative | +0.1% | Nasdaq notified the company of a minimum bid price deficiency. |
| Apr 28 | Fiscal 2025 earnings | Negative | -5.7% | Revenue declined and the company reported a fiscal-year net loss. |
| Apr 06 | Dual-class share structure | Neutral | +1.2% | The company implemented a dual-class share structure after shareholder approval. |
| Feb 10 | Chairman shareholder letter | Positive | -2.9% | Management outlined research, regulatory, production, and commercial milestones. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions were mixed, with earnings weakness aligning with downside while other corporate updates produced divergent reactions.
Key Terms
material non-public information regulatory
good manufacturing practices for veterinary drugs technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Jilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today issued the following statement in response to recent unusual trading activity in the price and trading volume of its Class A ordinary shares.
The Company does not normally comment on market activity or rumors. However, in light of the magnitude of the recent trading activity in the Company's securities, the Company is providing the following statement.
The Company confirms that it is not aware of any material non-public information regarding the Company, its business, financial condition, or operations that would account for the recent increase in trading activity in its securities. The Company's business operations continue in the ordinary course, and there have been no undisclosed corporate developments, transactions, or events that management believes would explain the recent price or volume movements.
The Company has been in contact with Nasdaq regarding the recent increase in trading volume of the shares of the Company and will continue to cooperate with Nasdaq and other relevant regulatory authorities as appropriate.
Shareholders and prospective investors are cautioned to exercise care when evaluating the Company's securities in light of the recent volatility and to rely only on information contained in the Company's filings with the U.S. Securities and Exchange Commission.
About Zhengye Biotechnology Holding Limited
Through Jilin Zhengye Biological Products Co., Ltd., the Company’s operating entity based in Jilin, China, Zhengye Biotechnology Holding Limited focuses on the research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For over 20 years, the operating entity has been committed to enhancing the health of animals. The operating entity has 50 veterinary vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity’s products are available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt as of the date of this press release. The operating entity has three veterinary vaccine production floors (including 13 vaccine production lines), one quality examination center, and one animal facility for vaccine development, all operating in accordance with Good Manufacturing Practices for Veterinary Drugs issued by the Ministry of Agriculture and Rural Affairs of the PRC. For more information, please visit the Company’s website: http://ir.jlzybio.com.
Forward-Looking Statements
This announcement contains statements that may constitute “forward-looking” statements which are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this announcement. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the United States Securities and Exchange Commission.
For more information, please contact:
Zhengye Biotechnology Holding Limited
Investor Relations Department
Email: ir@jlzybio.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
